Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report

[1]  M. Kloor,et al.  European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender , 2021, The British journal of surgery.

[2]  D. Bishop,et al.  Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial , 2020, The Lancet.

[3]  Correction: Cancer risk and survival in path _MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2020, Gut.

[4]  P. Møller.  The Prospective Lynch Syndrome Database reports enable evidence-based personal precision health care , 2020, Hereditary Cancer in Clinical Practice.

[5]  M. Kloor,et al.  Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report , 2019, Hereditary Cancer in Clinical Practice.

[6]  Aung Ko Win,et al.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.

[7]  P. Møller,et al.  The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome , 2019, Genetics in Medicine.

[8]  M. Kloor,et al.  Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report , 2019, Hereditary Cancer in Clinical Practice.

[9]  P. Møller,et al.  Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report , 2017, Hereditary cancer in clinical practice.

[10]  D. Evans,et al.  Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome , 2017, JAMA oncology.

[11]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[12]  P. Møller,et al.  Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database , 2016, Gut.

[13]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[14]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[15]  F. Couch,et al.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. , 2006, JAMA.

[16]  M. Munsell,et al.  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. , 2006, The New England journal of medicine.